What is the latest market price of tremelimumab?

Tremelimumab is an immune checkpoint inhibitor targeting CTLA-4, which is used to enhance the patient's own immune system's ability to recognize and kill tumors. Unlike traditional chemotherapy, temsitumumab blocks CTLA-4 signaling to more fully activate T cells, thereby improving the body's immune response to tumors. This mechanism of action makes it potentially valuable in the treatment of various types of hepatocellular carcinoma and non-small cell lung cancer (NSCLC), especially in combination therapy with PD-1/PD-L1 antibodies, which can exert a synergistic effect and improve disease control rates.

In terms of market price, temsitumumab has not yet been officially launched in mainland China, so it has not yet been included in medical insurance reimbursement. According to overseas and Hong Kong market information, the commonly used specifications are300mg/15ml, and the price of each bottle is about 100,000 yuan. Because it is an innovative immune drug, its research and development costs are high and the production process is complex, so the price is relatively high. There is currently no generic version on the market, which means that patients can only rely on the supply of the original drug when using it. The price level not only reflects the R&D investment of drugs, but also reflects the technical barriers of global biopharmaceutical companies in the field of immuno-oncology drugs.

In addition, the use of temsitumumab is not limited to monotherapy. In clinical trials and practice, it is often used in combination with other immune checkpoint inhibitors, such asPD-1 or PD-L1 antibodies, to further enhance the therapeutic effect through dual immune regulation. This combination regimen has shown the potential to delay disease progression in patients with advanced tumors and has become a hot topic in global cancer treatment research.

Overall, temsitumumab is an innovative drug in immuno-oncology treatment, and its high price reflects the cost of R&D, production and clinical verification of the original drug. If domestic patients want to use this drug, they need to purchase overseas or Hong Kong original drugs through formal channels and fully understand their uses, indications and potential financial burdens.

Reference: https://www.drugs.com/mtm/tremelimumab.html